title: FEZ1/LZTS1 protein expression in ovarian cancer.
abstract: The FEZ1/LZTS1 (FEZ1) gene maps to chromosome 8p22 and is frequently altered in human cancer. FEZ1 has been proposed as a candidate tumour suppressor gene and its loss may contribute to tumour progression. We have analysed the expression of FEZ1 protein in tissues from ovarian carcinomas in relation to clinico-pathological variables, response to chemotherapy and disease-free and overall survival. FEZ1 status was assessed by immunohistochemistry. Cytoplasmic staining for FEZ1 protein was absent or drastically reduced in 38% of tumours. FEZ1 protein expression was not related to tumour grade, histotype, disease-free survival, or overall survival. On the contrary, it was significantly correlated with age and with FIGO stage of disease. This finding indicates that FEZ1 is involved in ovarian carcinogenesis. Moreover, loss of FEZ1 protein significantly predicted a complete treatment response in patients who received taxane-based chemotherapy. In conclusion, the reduction or loss of FEZ1 protein could be an aid to the clinical management of patients affected by ovarian carcinoma.
authors.affiliation: Istituto Nazionale dei Tumori, Napoli, Italy.
authors.forename: Daniela
authors.initials: D
authors.lastname: Califano
authors.forename: Sandro
authors.initials: S
authors.lastname: Pignata
authors.forename: Carmela
authors.initials: C
authors.lastname: Pisano
authors.forename: Stefano
authors.initials: S
authors.lastname: Greggi
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Laurelli
authors.forename: Nunzia Simona
authors.initials: NS
authors.lastname: Losito
authors.forename: Alessandro
authors.initials: A
authors.lastname: Ottaiano
authors.forename: Adolfo
authors.initials: A
authors.lastname: Gallipoli
authors.forename: Rosa
authors.initials: R
authors.lastname: Pasquinelli
authors.forename: Veronica
authors.initials: V
authors.lastname: De Simone
authors.forename: Roberto
authors.initials: R
authors.lastname: Cirombella
authors.forename: Alfredo
authors.initials: A
authors.lastname: Fusco
authors.forename: Gennaro
authors.initials: G
authors.lastname: Chiappetta
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D002277:Carcinoma / Q000737:chemistry* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D003593:Cytoplasm / Q000737:chemistry; D004268:DNA-Binding Proteins / Q000032:analysis*; D018572:Disease-Free Survival; D015536:Down-Regulation; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D018570:Risk Assessment; D043823:Taxoids / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D025521:Tumor Suppressor Proteins / Q000032:analysis*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004268:DNA-Binding Proteins; C118711:LZTS1 protein, human; D043823:Taxoids; D025521:Tumor Suppressor Proteins